Targeting hyperinflammation in infection: can we harness the COVID-19 therapeutics momentum to end the dengue drugs drought?

McBride, Angela; Mehta, Puja; Rivino, Laura; Ramanan, Athimalaipet V; Yacoub, Sophie

McBride, Angela; Mehta, Puja; Rivino, Laura; Ramanan, Athimalaipet V; Yacoub, Sophie.

McBride A; Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK.
Mehta P; Oxford University Clinical Research Unit, Ho Chi Minh City 70000, Vietnam.
Rivino L; Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, London, UK.
Ramanan AV; Department of Rheumatology, University College London Hospital, London, UK.
Yacoub S; School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Lancet Microbe ; 2(7): e277-e278, 2021 07.

Article in English | MEDLINE | ID: covidwho-1193551

Subject(s)

COVID-19; Dengue; Dengue/drug therapy; Droughts; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Dengue / COVID-19 Limits: Humans Language: English Journal: Lancet Microbe Year: 2021 Document Type: Article Affiliation country: S2666-5247(21)00087-2

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google